Palatin Technologies Unveils Significant Progress in Dry Eye Disease Treatment with PL9643 at ARVO 2025 Palatin Technologies presents groundbreaking results from the Phase 3 PL9643 clinical trial at ARVO 2025, indicating potential for full symptom resolution in dry eye disease.

Palatin Technologies Unveils Significant Progress in Dry Eye Disease Treatment with PL9643 at ARVO 2025 #Palatin_Technologies #Dry_Eye_Disease #PL9643

Palatin's PL9643 Shows Promise as First-in-Class Therapy for Dry Eye Disease Palatin Technologies announces significant findings from the Phase 3 MELODY-1 trial, revealing PL9643 as a potential first-in-class treatment for dry eye disease, delivering full symptom resolution.

Palatin's PL9643 Shows Promise as First-in-Class Therapy for Dry Eye Disease #United_States #Cranbury #Dry_Eye_Disease #Palatin #PL9643